Journal of Food and Nutrition Research
ISSN (Print): 2333-1119 ISSN (Online): 2333-1240 Website: http://www.sciepub.com/journal/jfnr Editor-in-chief: Prabhat Kumar Mandal
Open Access
Journal Browser
Go
Journal of Food and Nutrition Research. 2020, 8(4), 212-215
DOI: 10.12691/jfnr-8-4-8
Open AccessArticle

Efficacy of Berberis aristata Compared to Metformin in Improving Glycemic Control and Insulin Resistance in Patients with Type 2 Diabetes Mellitus

Giuseppe Derosa1, 2, , Giovanni Gaudio3, Angela D’Angelo1, 2 and Pamela Maffioli1

1Department of Internal Medicine and Therapeutics, University of Pavia, PAVIA, Italy

2Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy

3Internal Medicine Division, Ospedale Angelo Bellini, Somma Lombardo, VARESE, Italy

Pub. Date: June 03, 2020

Cite this paper:
Giuseppe Derosa, Giovanni Gaudio, Angela D’Angelo and Pamela Maffioli. Efficacy of Berberis aristata Compared to Metformin in Improving Glycemic Control and Insulin Resistance in Patients with Type 2 Diabetes Mellitus. Journal of Food and Nutrition Research. 2020; 8(4):212-215. doi: 10.12691/jfnr-8-4-8

Abstract

Aim: the study was aimed to evaluate the action of a combination of an extract of Berberis aristata/Silybum marianum compared to metformin in a sample of Caucasian type 2 diabetic patients not taking anti-diabetic drugs. Methods: we enrolled 109 type 2 diabetic patients and randomized them to take Berberis aristata/Silybum marianum 588/108 mg or metformin for 6 months, in a double-blind, randomized, controlled, clinical trial. Results: glycated hemoglobin was similarly reduced by both Berberis aristata/Silybum marianum and metformin (p < 0.05 vs baseline, for both treatments), without significant differences between the two treatments. The same trend was recorded for FPG (p < 0.05 vs baseline, for both treatments), and PPG (p < 0.01 vs baseline, for both treatments). Both treatment reduced FPI and HOMA-IR (p < 0.05 vs baseline), without any differences between the two arms. Both Berberis aristata/Silybum marianum and metformin improved TC, LDL-C and Tg compared to baseline (p < 0.05 for both); however, Berberis aristata/Silybum marianum better improved these parameters compared to metformin (p < 0.05 for all). Conclusions: Berberis aristata/Silybum marianum can be a valid alternative to metformin in patients not well controlled by diet.

Keywords:
Berberis aristata/Silybum marianum glycemic control metformin

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Shamseddeen, H., Getty, J.Z., Hamdallah, I.N., Ali, M.R., “Epidemiology and economic impact of obesity and type 2 diabetes”, Surg Clin North Am, 91(6). 1163-1172. Dec.2011.
 
[2]  Tielmans, A., Laloi-Michelin, M., Coupaye, M., Virally, M., Meas, T., Guillausseau, P., “Traitement médicamenteux du diabète de type 2 (première partie)” Presse Med 2007; 36: 269-278.
 
[3]  Chen, W. Miao, Y.Q., Fan, D.J., Yang, S.S., Lin, X., Meng, L.K., Tang, X., “Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats”, AAPS PharmSciTech, 12(2). 705-711. Jun.2011.
 
[4]  Pan, G.Y., Wang, G.J., Liu, X.D., Fawcett, J.P., Xie, Y.Y., “The involvement of P-glycoprotein in berberine absorption”, Pharmacol Toxicol, 91(4). 193-197. Oct.2002.
 
[5]  Di Pierro, F., Villanova, N., Agostini, F., Marzocchi, R., Soverini, V., Marchesini, G., “Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control”, Diabetes Metab Syndr Obes, 5, 213-217. Jul.2012.
 
[6]  Chang, W., Chen, L., Hatch, G.M., “Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies”, Biochem Cell Biol, 93(5). 479-486. Oct.2015.
 
[7]  Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., D' Angelo, A., Fogari, E., Maffioli, P., “Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients”, J Biol Regul Homeost Agents, 27(3). 717-728. Jul-Sep.2013.
 
[8]  Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., D'Angelo, A., Fogari, E., Maffioli, P., “Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients”, Expert Opin Biol Ther, 13(11). 1495-1506. Nov.2013.
 
[9]  The Council for International Organisation of Medical Sciences., “Proposed International Guidelines for Biomedical Research Involving Human Subjects”, Geneva, 1982.
 
[10]  Rydén, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I., Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., Priori, S.G., Blanc, J.J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J.L., Deckers, J.W., Bertrand, M., Charbonnel, B., Erdmann, E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J.R., Graham, I., Monteiro, P.F., Parhofer, K., Pyörälä, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD), “Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European As
 
[11]  Lichtenstein, A.H., Appel, L.J., Brands, M., Carnethon, M., Daniels, S., Franch, H.A., Franklin, B., Kris-Etherton, P., Harris, W.S., Howard, B., Karanja, N., Lefevre, M., Rudel, L., Sacks, F., Van Horn, L., Winston, M., Wylie-Rosett, J., “Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006”, Arterioscler Thromb Vasc Biol, 26. 2186-2191. Oct.2006.
 
[12]  Winer, B.J., “Statistical Principles in Experimental Design”, 2nd ed., McGraw-Hill, New York (USA), 1971.
 
[13]  Yin, J., Zhang, H., Ye, J., “Traditional Chinese medicine in treatment of metabolic syndrome”, Endocr Metab Immune Disord Drug Targets, 8(2), 99-111. Jun.2008.